At Polpharma Group, all our efforts are focused on delivering high-quality and affordable medicines to as many communities as possible.
For over 80 years, trusted by patients, healthcare professionals, and business partners alike. A leading regional (CEE and CIS) manufacturer of pharmaceuticals and a leader in the Polish & Kazakhstan pharmaceutical market. Actively operating in Central and Eastern Europe, the Caucasus, and Central Asia markets.
Every day we diligently cooperate with doctors, pharmacists, and other healthcare professionals to better understand every stage of a patient’s journey and ensure that our patients receive and stick to the most adequate treatment.
Thanks to best-in-class industry talents and state-of-the-art technologies, we are able to design and deliver crucial products and solutions to address the biggest health challenges (an aging population, chronic diseases) and healthcare system problems (increasing healthcare costs, resource shortages).
Through collaboration with our partners, we explore new ways of doing business and accelerate positive changes.
Polpharma Group Overview
- A leading regional (CEE and CIS) manufacturer of pharmaceuticals
Transforming the healthcare industry in terms of advanced commercial
models and the usage of AI to improve both the closeness to the HCP
professionals and patients and its effectiveness
For over 85 years, trusted by patients, healthcare professionals,
and business partners alike.
Shymkent, Staraya Kupavna
Russia & Kazachstan
on Bayer technology
of Polpharma after
The Second World War.
1949First product after
the war – redistilled
water in glass
1951Minister of Industry
making salicylates and
1959Plant becomes part of Union Of Pharmaceutical Industry and renames to Pharmaceutical Works "Polfa" Starogard
1995,,Polfa" Starogard transformed into a Join Stock Company with 100% shares belonging to the State Treasury
1995Company returned to its old name - Pharmaceutical Works POLPHARMA S.A.
2000Spectra Holding and Prokom Investments (Polish capital) bought the majority of the Company shares converting it to a private company
2007Strategic alliance with Akrikhin, major generic pharma player in the Russian market
2010Acquisition of antibiotic business of Bioton Poland together with a cephalosporin manufacturing plant in Duchnice, Poland
2011Polpharma becomes a key partner of Chimpharm, Kazahstan
2012Polpharma becomes a major shareholder of Polfa Warsaw, Poland
2012First laboratories are opened in a biotech center in the Gdańsk Science and Technology Park
2014Decision about building BIOTECH Manufacturing facility in Duchnice
2017Decision about Parental Manufacturing consolidation and building new facility for sterile products in Starogard
2018FDA audyt for API Plant
2019Spin-off of Biotech buissness as Polpharma Biologics SA
2019Completion of the investment in Sieradz (non-sterile liquids)
2020Integration IPOCHEM to Polpharma API
2022Groundbreaking for High Potent API R&D and Production facility
We support patients’ health and the sustainable development of the Polpharma Group by being a reliable and responsible manufacturer of high-quality APIs
We are proud of our 70 years of experience in supporting patients’ health with high quality APIs and becoming a leading European CDMO partner.
Our core competencies are a solid foundation to assure customer satisfaction through the highest quality of products delivered with environment-friendly processes. At our FDA-approved plant located in Central Europe, we provide end-to-end solutions from API development to scale-up, allowing smooth process transfer for commercial-scale manufacturing capabilities with a world-class regulatory support.
- From process development to large scale production
Highest quality of products
and cost-competitive processes
- Cost competitive vs. Western EU, US, JP
- European location of manufacturing plants
Fast decision making and execution
- Fully integrated Business Unit, a lean organization
Sales % Per Region
Polpharma utilizes up-to-date technologies, which ensure the safety of products, employees, and the natural environment.
We have the capabilities to provide customers with materials ranging from clinical quantities up to in-market supply. We have full and vertical integration of processes from R&D, pilot plant, scale-up to the manufacturing leverage of our competencies in place so that cost-effective and on-time solutions are delivered to our partners. API manufacturing is carried out in cGMP-compliant and FDA-approved multipurpose plant.
Starogard Gdanski Site View
Manufacturing Site: 33,1 ha
Area dedicated to:
POLPHARMA API PRODUCTION: 6,2 ha
Warehousing: 3,0 ha
(tank farm and solid raw materials)
Wastewater treatment plant: 4,1 ha
Total Building Surface in Starogard: 123.498 m2
Buildings dedicated to:
Polpharma API production: 19.246 m2
Warehousing: 10.735 m2
Six multipurpose buildings, Pilot Plant,
Warsaw Site View
Manufacturing Site: 1 ha
- Production of API
- Production of intermediates for API synthesis
- Total headcount: 50
- Four-story synthesis plant
- Facility for API’s physical processing